Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q9DK
|
|||
| Former ID |
DAP000339
|
|||
| Drug Name |
Nizatidine
|
|||
| Synonyms |
Acinon; Antizid; Axid; Calmaxid; Cronizat; Distaxid; Galitidin; Gastrax; Naxidine; Niatidine; Nizatidina; Nizatidinum; Nizax; Nizaxid; Panaxid; Tazac; Ulcosol; Ulxid; Zanizal; Zinga; Axid Ar; Nizatidina [Spanish]; Nizatidinum [Latin]; Splendil ER; LY 139037; Acinon (TN); Axid (TN); LY-139037; Tazac (TN); ZE-101; ZL-101; Nizatidine (JAN/USP/INN); Nizatidine [USAN:BAN:INN:JAN]; N-(2-(((2-((Dimethylamino)methyl)-4-thiazolyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N-(4-(6-Methylamino-7-nitro-2-thia-5-aza-6-hepten-1-yl)-2-thiazolylmethyl)-N,N-dimethylamin; (E)-1-N'-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-[2-[[2-(dimethylaminomethyl)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acid-reflux disorder [ICD-11: DA22; ICD-9: 530.81] | Approved | [1], [2] | |
| Therapeutic Class |
Antiulcer Agents
|
|||
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H21N5O2S2
|
|||
| Canonical SMILES |
CNC(=C[N+](=O)[O-])NCCSCC1=CSC(=N1)CN(C)C
|
|||
| InChI |
1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+
|
|||
| InChIKey |
SGXXNSQHWDMGGP-IZZDOVSWSA-N
|
|||
| CAS Number |
CAS 76963-41-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9479, 7847506, 7980136, 10047729, 11112849, 12012865, 14801956, 26719892, 36077514, 46386765, 46507554, 48395159, 48416335, 49648463, 49968698, 57352747, 80039644, 85175204, 85209480, 92308159, 92308434, 92711372, 93166919, 103091650, 103157346, 103189241, 111634652, 117377111, 117480196, 119526527, 124658842, 124801333, 124882685, 126630925, 131269073, 131326051, 134337651, 135011516, 135692320, 137005454, 142971063, 144075999, 144089140, 152040062, 160963930, 172080209, 177748315, 178103822, 179116550, 179148990
|
|||
| ChEBI ID |
CHEBI:7601
|
|||
| ADReCS Drug ID | BADD_D01582 | |||
| SuperDrug ATC ID |
A02BA04
|
|||
| SuperDrug CAS ID |
cas=076963412
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.623; p = 0.03). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.506; p = 0.039). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.574; p = 0.036). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.573; p = 0.012). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.451; p = 0.045). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.609; p = 0.011). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.514; p = 0.04). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.623; p = 0.015). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.505; p = 0.032). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.551; p = 0.034). | |||
|
Studied Microbe: Parabacteroides johnsonii DSM 18315
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Parabacteroides johnsonii DSM 18315 (log2FC = -0.426; p = 0.003). | |||
|
Studied Microbe: Parabacteroides merdae ATCC 43184
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Parabacteroides merdae ATCC 43184 (log2FC = -0.422; p = 0.033). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium breve DSM 20213
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Nizatidine can be metabolized by Bifidobacterium breve DSM 20213 (log2FC = -0.952; p = 0.001). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4], [5] | |||
| Metabolic Reaction | N-oxide reduction | |||
| Resulting Metabolite | Hydroxyiminoranitidine | |||
| Metabolic Effect | Decrease activity | |||
| Description | Nizatidine can be metabolized to Hydroxyiminoranitidine by gut microbiota through N-oxide reduction, which results in the decrease of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H2 receptor (H2R) | Target Info | Antagonist | [6] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gastric acid secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Histamine H2 receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Histamine H2 Receptor and Histamine | |||
| Gastric Acid Production | ||||
| Reactome | Histamine receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7248). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075616. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013 Nov;94(5):574-81. | |||
| REF 5 | The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2016;12(1):31-40. | |||
| REF 6 | Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.